FundedIQ
Biotechnology

Virpax Pharmaceuticals Inc.: Funding, Investors & Team (Nov 2026)

Virpax® is focused on developing and commercializing non-addictive pain products. Virpax has global rights to an intranasal New Chemical Entity (NCE) that deliverers enkephalin to the brain utilizing a Nanoparticle-Molecular Envelope Technology (MET) to manage chronic pain, cancer pain, and post-traumatic stress disorder (Post-Traumatic Stress Disorder (PTSD). “Enkephalins are naturally occurring analgesics in our body that bind predominantly to the delta-receptor. Delta opioid receptors have a built-in mechanism for pain relief. They can be precisely targeted with drug-delivering nanoparticles, making them a promising target for treating chronic inflammatory pain with fewer side effects” (Journal of Controlled Release). Virpax has the rights to two 505b2 product candidates; an "NSAID" Topical Spray Film Delivery Technology for localized musculoskeletal pain, and an injectable “local anesthetic” Liposomal Hydro-Gel Technology for postoperative pain management. MMS019, is an intranasal Nanoparticle-MET liquid dispersion being developed to help prevent viral spread caused by influenza and SARS-CoV-2. Future product candidates will include treatments for neurological disorders.

virpaxpharma.com LinkedIn Berwyn, United States 1-10 employees
Biotechnology Health Care Life Science Market Research Marketing Medical Device Neuroscience Product Research
Total raised
$58.0M
Rounds
2
Latest
Post-IPO Equity
Sep 2021

Virpax Pharmaceuticals Inc. has raised $58.0M across 2 funding rounds on record, the most recent a Post-IPO Equity of $40.0M announced in Sep 2021.

That round is above the $8.9M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Virpax Pharmaceuticals Inc. Company Profile and Key Stats

Total funding raised
$58.0M
across 2 rounds on record
Funding rounds on record
2
Latest funding round
Post-IPO Equity
$40.0M in Sep 2021
Employees
1-10
reported band
Headquarters
Berwyn, United States

Latest funding round on record: Sep 2021.

Virpax Pharmaceuticals Inc. Funding Rounds

Date
Round
Amount
Post-IPO Equity
$40.0M
Series C
$18.0M

Virpax Pharmaceuticals Inc. raised $18.0M in a Series C announced in Feb 2021.

7 months later, a Post-IPO Equity of $40.0M was announced in Sep 2021.

Virpax Pharmaceuticals Inc. Founders and Leadership Team

Name
Role
Contact
Anthony Mack
CEO
Locked

Contact details for the Virpax Pharmaceuticals Inc. team: 1 of 1 has an email address on file.

Start 14-day free trial →

Virpax Pharmaceuticals Inc. Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round

Virpax Pharmaceuticals Inc.'s latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Virpax Pharmaceuticals Inc. in Biotechnology and Berwyn

Companies Similar to Virpax Pharmaceuticals Inc.

Araceli Biosciences specializes in creating scientific instruments for discovering tissue- and cell-based…

Seed $4.5M

Switchpoint Bio is a biotechnology company that offers immune relevant drug treatments.

Pre-Seed $5.3M

Nanopath Inc. is a company that specializes in molecular diagnostics and allows for fast, high-quality…

Series B $25.0M

Frontier Bio is creating lab-grown human tissues as an ethical replacement for animal studies and is setting…

Undisclosed round $380k

Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel…

Series C $100M

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus…

Series B $41.9M

Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…

Series A $6.0M

Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…

Series D —

Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…

Undisclosed round $21.5M

100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…

Pre-Seed $110k

MEND is a company focused on life sciences, determined to assist individuals in achieving better health…

Undisclosed round $1.5M

Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…

Series B $50.0M

Virpax Pharmaceuticals Inc. Funding FAQs

What does Virpax Pharmaceuticals Inc. do?

Virpax® is focused on developing and commercializing non-addictive pain products. Virpax has global rights to an intranasal New Chemical Entity (NCE) that deliverers enkephalin to the brain utilizing a Nanoparticle-Molecular Envelope Technology (MET) to manage chronic pain, cancer pain, and post-traumatic stress disorder (Post-Traumatic Stress Disorder (PTSD). “Enkephalins are naturally occurring analgesics in our body that bind predominantly to the delta-receptor. Delta opioid receptors have a built-in mechanism for pain relief. They can be precisely targeted with drug-delivering nanoparticles, making them a promising target for treating chronic inflammatory pain with fewer side effects” (Journal of Controlled Release). Virpax has the rights to two 505b2 product candidates; an "NSAID" Topical Spray Film Delivery Technology for localized musculoskeletal pain, and an injectable “local anesthetic” Liposomal Hydro-Gel Technology for postoperative pain management. MMS019, is an intranasal Nanoparticle-MET liquid dispersion being developed to help prevent viral spread caused by influenza and SARS-CoV-2. Future product candidates will include treatments for neurological disorders.

How much funding has Virpax Pharmaceuticals Inc. raised?

Virpax Pharmaceuticals Inc. has raised $58.0M across 2 rounds on record. The most recent is a Post-IPO Equity of $40.0M announced in Sep 2021.

When did Virpax Pharmaceuticals Inc. last raise funding?

Virpax Pharmaceuticals Inc.'s most recent funding round on record is a Post-IPO Equity of $40.0M, announced in Sep 2021.

Who is the CEO of Virpax Pharmaceuticals Inc.?

Anthony Mack is listed as CEO at Virpax Pharmaceuticals Inc..

Where is Virpax Pharmaceuticals Inc. headquartered?

Virpax Pharmaceuticals Inc. is based in Berwyn, Pennsylvania, United States.

How many employees does Virpax Pharmaceuticals Inc. have?

Virpax Pharmaceuticals Inc. is in the 1-10 employee band.

How does Virpax Pharmaceuticals Inc.'s funding compare to other Biotechnology startups?

Virpax Pharmaceuticals Inc.'s latest round of $40.0M is above the $8.9M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.

About FundedIQ's Virpax Pharmaceuticals Inc. Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Virpax Pharmaceuticals Inc. is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.

Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.